Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.

Pratt, Guy; El-Sharkawi, Dima; Kothari, Jaimal; D'Sa, Shirley; Auer, Rebecca; McCarthy, Helen; Krishna, Rajesh; Miles, Oliver; Kyriakou, Charalampia; Owen, Roger

Pratt, Guy; El-Sharkawi, Dima; Kothari, Jaimal; D'Sa, Shirley; Auer, Rebecca; McCarthy, Helen; Krishna, Rajesh; Miles, Oliver; Kyriakou, Charalampia; Owen, Roger.

Afiliação

Pratt G; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
El-Sharkawi D; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
Kothari J; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
D'Sa S; University College London Hospitals NHS Foundation Trust, London, UK.
Auer R; Barts Health NHS Trust, London, UK.
McCarthy H; University Hospitals Dorset NHS Foundation Trust, Dorset, UK.
Krishna R; University Hospitals of Leicester NHS Trust, Leicester, UK.
Miles O; Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
Kyriakou C; University College London Hospitals NHS Foundation Trust, London, UK.
Owen R; London North West University Healthcare NHS Trust, London, UK.

Br J Haematol ; 197(2): 171-187, 2022 04.

Article em En | MEDLINE | ID: mdl-35020191

Assuntos

Hematologia; Macroglobulinemia de Waldenstrom; Cloridrato de Bendamustina/uso terapêutico; Bortezomib/uso terapêutico; Humanos; Rituximab/uso terapêutico; Macroglobulinemia de Waldenstrom/tratamento farmacológico; Macroglobulinemia de Waldenstrom/terapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Macroglobulinemia de Waldenstrom / Hematologia Tipo de estudo: Diagnostic_studies / Guideline / Systematic_reviews Limite: Humans Idioma: En Revista: Br J Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google